Saturday, March 21, 2015 7:16:19 AM
Shareholders accept the true guidance of Dr. Robert Pierce and what his goals and planning are. As a medical science person I concur exactly with Dr. Pierce from the 1st day he joined $ONCS. The plan is very simple in making $ONCS Melanoma next trial a Pivotal P2B Combo with Merck's Keytruda and then apply for a Commercial BLA.
As I have stated it is absolutely unprecedented that the FDA has allowed $ONCS to proceed from a safety/tolerability P1/2A EP+IL-12 directly to an efficacy Combo P2B Keytruda + EP+IL-12.
To science medical persons this means that Dr. Pierce and the FDA have worked on an agreed Protocol for which the expected successful results in greater ORR for the Combo vs either alone will lead to Commercial BLA approval of $ONCS EP+IL-12 as an adjunct with Keytruda.
Recent ONCSQ News
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 07:30:19 PM
Alliance Creative Group (ACGX) Releases Q3 2024 Financial and Disclosure Report with an increase of over 100% in Net Income for 1st 9 months of 2024 vs 2023 • ACGX • Nov 14, 2024 8:30 AM
Unitronix Corp. Publishes Its Cryptocurrency Portfolio Strategy • UTRX • Nov 14, 2024 8:05 AM
Avant Technologies and Ainnova Tech Form Joint Venture to Advance Early Disease Detection Using Artificial Intelligence • AVAI • Nov 12, 2024 9:00 AM
Swifty Global Announces Launch of Swifty Sports IE, Expanding Sports Betting and Casino Services in the Irish Market • DRCR • Nov 12, 2024 9:00 AM
Oohvie App Update Enhances Women's Health with Telemedicine and Online Scheduling • HLYK • Nov 11, 2024 8:00 AM
SANUWAVE Announces Record Quarterly Revenues: Q3 FY2024 Financial Results • SNWV • Nov 8, 2024 7:07 AM